Updated 07:15 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,856.50 -0.77% CL 89.08 +0.59% BTC 64,493.46 -1.24%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,857 −0.77% BTC $64,493 −1.24% VIX 19.30 +3.21% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Care Facilities

Ardent Health, Inc. logoArdent Health, Inc.

ARDT · the NYSE · USD · Market cap $2.2B · 19,500 employees

Ardent Health, Inc.

FAIL · Does not pass the screen
17.80 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price17.80 USD at the 13 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 4.33)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $14.00 to $34.51, base estimate $14.00 (screen dated 2026-11-13).

Current read
Markup ?
Overvalued · screened 2026-11-13
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 4.33, read 2026-11-15
  • Ethical does not pass the values gate
Price17.80 USD
Fair value14.00
Ethical score70.0/100
Value readOvervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-11Read Markup17.93-0.7% to today Accumulation gives way to Markup after a 68% rise in 4 weeks
2026-10-11Read Accumulation10.68+66.7% to today ✓Markdown gives way to Accumulation
2026-09-24Read Markdown10.61+67.8% to today Accumulation gives way to Markdown with volume flow in agreement
2026-07-21Read Accumulation10.15+75.4% to today ✓Distribution gives way to Accumulation after a 9% rise in 3 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Ardent Health, Inc. holds its Markup at $17.80. The statistical read favours the buyers, held for 8 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateThe statistical read favours the buyers, held for 8 days
Price at the screen$17.80
Valuation29.44 trailing · 12.67 forward price to earnings
Values screenFAIL · score 70.0
Beta0.58
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 43.82% Below 33% Interest-bearing debt is 43.8% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 26.38% Below 49% Money owed to the company is 26.4% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Ardent Health,'s business is in a permissible area, but its interest-bearing debt is about 44% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ARDT's ethical verdict changes

Today ARDT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $14.00 fair value estimate.

How a fair value is estimated: discounted cash flow (DCF).

14.00Conservative14.00Base case34.51Growth case 17.80Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 27.1% above the base estimate.

The Street's Range
10.50Street low 13.00Street average 14.00Street high 17.80Price

Third-party analyst targets: 12 covering, consensus Buy. The average target sits −27% from the screen price.

Reading the gap · Both our model and the Street see limited upside at this price.

Price History & Projections

Where our models see it going: fair-value estimate $14.00, with a range of $14.00 to $34.51, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Hospitals Treating Real Patients Trade at a Discount

Picture a local clinic where a family gets care after an accident or a routine check. The cash still has to flow through operators that run dozens of these sites across states. Ardent Health owns and manages that network yet carries an opportunity rating of none despite a forward multiple of 8.2 times and revenue growth near 7 percent.

The balance sheet shows a 2 percent profit margin alongside 14 percent return on equity and an ethical screen that clears cleanly. Analyst consensus sits at buy with a median target of 12 dollars. Those figures look steady on paper but the unknown moat and slim margins leave little room for error when reimbursement rates shift.

Healthcare operators face constant pressure from regulation and payer mix that can erode even modest profits quickly. Thin returns also mean any slowdown in patient volumes hits earnings hard and leaves valuation looking less attractive than it first appears. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E12.7xreasonably valued
Trailing P/E29.4xa premium valuation
EPS, trailing0.54
EPS, forward1.26
Revenue growth-1.4%revenue is shrinking
Profit margin1.2%barely profitable
Return on equity10.0%a modest return on shareholder capital
FCF yield9.29%
Debt to equity1.30a meaningful debt load worth watching
Current ratio2.11comfortably covers its short-term bills
Beta0.58steadier than the market
Short interest, float0.12%
52-week range7.71 - 16.23
Market cap$2.2B
Employees19,500

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ARDT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-11 Markup · changed $17.93 +53.1% Entry 20

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 53.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. Since the last review it its composite score eased.

2026-11-04 Accumulation $11.71 -2.7% Entry 19

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Accumulation $12.03 +0.0% Entry 18

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Accumulation $12.03 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation $12.03 +0.8% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation $11.93 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Accumulation $11.93 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Accumulation $11.93 -3.5% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Accumulation $12.36 +0.0% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Accumulation $12.36 +1.3% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ARDT

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ARDT's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $9.95 -5.8% · $942 -5.8%
2 months $9.40 -0.3% · $997 -0.3%
3 months $9.24 +1.4% · $1,014 +1.4%
6 months $8.73 +7.3% · $1,073 +7.3%
1 year $13.42 -30.2% · $698 -30.2%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ARDT does next, these words stay.

Ardent Health, Inc. · ARDT · Markup · $17.80
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.